DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the DHANSA LABS LIMITED (DHANSA) share price today?

DHANSA LABS LIMITED (DHANSA) is trading at ₹21.85 on the NSE, down 5.00% on the day. Source: DocStoX.

What is the PE ratio of DHANSA LABS LIMITED?

DHANSA LABS LIMITED has a price-to-earnings (PE) ratio of 9.5 in the Commodities sector.

What is the market capitalisation of DHANSA LABS LIMITED?

DHANSA LABS LIMITED has a market capitalisation of approximately ₹58 crore.

DHANSA LABS LIMITED

DHANSA·NSE·Commodities

₹21.85▼ -1.15 (-5.00%)

Commodities · Fertilizers & Agrochemicals

A steady, established business

Day₹21.85

₹22.15

52W₹19

₹2545%

Open

₹21.90

High

₹22.15

Low

₹21.85

Prev Close

₹23.00

Volume

14.0K

VWAP

₹21.90

Snapshot

Key fundamentals

Market Cap

₹58 Cr

P/E Ratio

9.50Cheap

P/B Ratio

0.64

EPS

₹2.30

Book Value

₹39.70

ROE

6.53%Weak

ROCE

8.00%Weak

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹10.00

52W High

₹25.45

52W Low

₹18.90

Sector

Commodities

Industry

Fertilizers & Agrochemicals

Buy

None moatHigh uncertainty

Fair value estimate

₹39

▲ 77.4%upside

Trading at ₹22 — 77% below our estimate

BearFair valueBull

₹33₹39₹45

/100

Business quality — Watch the fundamentals

Growth 34Profitability 10Efficiency 0Valuation 100

Plain English

Our view

A steady, established business
Reasonably priced at 10× earnings
Weak returns on equity (7%)

Strengths

Reasonably priced at 10× earnings
Promoters hold a controlling stake

Risks

Weak returns on equity (7%)
Fundamental red flags (Piotroski 0/9)

How we got there

Fair value methods

Residual income

7% ROE fading to 14% over ~3 yrs, on ₹40 book

₹36

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹45

Analyst target

No analyst coverage

—

Blended fair value₹39

What the numbers say

Investment thesis

Bull case

Reasonably priced at 10× earnings
Promoters hold a controlling stake

Bear case

Weak returns on equity (7%)
Fundamental red flags (Piotroski 0/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

9.5Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

6.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

8.0%Weak

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

₹58 Cr

P/B

0.64

EPS

₹2.30

Div Yield

—

What changed

Recent changes

Domestic institutions-0.4% stake last quarter
Promoters-5.10% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 9.5×

Growth

Steady

+11% rev CAGR

Profitability

Modest

6.5% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %85.7%

Turnover₹3.07L Cr

Trades5

VWAP₹21.90

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+10.6%

+11.6%

10Y

—

Profit

+6.3%

-9.7%

10Y

—

EPS

-57.3%

-59.5%

10Y

—

Profile

Pros

Stock is trading at 0.58 times its book value

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of 11.6% over past five years.
Company has a low return on equity of 11.0% over last 3 years.
Company might be capitalizing the interest cost
Debtor days have increased from 103 to 139 days.
Working capital days have increased from 115 days to 169 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Promoters trimmed their stake by 5.10 pts; domestic institutions reduced 0.39 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

65%

Promoter

Promoters

65.0%-5.10

Public

34.6%+5.50

FII / FPI

0.0%0.00

DII

0.3%-0.39

Total shareholders

1,200-24 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter65.05%

DII0.33%

Public34.63%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.[1]